Skip to main content
Evotec secures $2.9 million Gates grant
Image for illustrative purposes only. Not a real photo.

Evotec secures $2.9 million Gates grant

By

Key points

  • Evotec secured a $2.9 million Gates Foundation grant to continue its human stem cell-based drug safety research.
  • The initial three-year collaboration screened more than 5,000 compounds across nine global health research programs.
  • The new funding extends the project for another three years, maintaining access to technology that identifies potential fetal development risks earlier in drug discovery.

Evotec (NASDAQ:EVO) has secured a $2.9 million Gates Foundation grant to extend its human stem cell-based drug safety research for another three years.

The new funding continues a project launched in 2023, following an initial Gates Foundation grant of $2,529,856 for the same fetal development risk screening platform.

During the initial three-year collaboration, the platform screened more than 5,000 compounds across nine grantee programs using human induced pluripotent stem cell models and industrial-scale screening capabilities.

Evotec's wider New Approach Methodologies portfolio includes more than 25 human stem cell-derived cellular models, three-dimensional organoid systems, AI-supported disease modelling and industrial-scale screening technologies.

The platform is designed to identify potential teratogenic effects, or risks to fetal development, earlier in drug discovery, helping researchers assess drug candidates before advancing them into clinical testing.


Frequently asked questions